Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2015

01.06.2015 | review

New targets in gastric cancer

verfasst von: MD, PhD Nikita M. Volkov

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer-related death worldwide. Since the effectiveness of current therapeutic options for the treatment of advanced (inoperable locally advanced, recurrent, or metastatic) disease is limited the need for novel effective treatment options is obvious. During last 2 decades, molecular-targeted therapy emerged as a new promising treatment modality and showed pronounced success in many tumor types. But in GC the only targeted agent approved until recently was trastuzumab for human epidermal growth factor receptor (HER) 2-positive advanced disease. Recently ramucirumab has emerged as new treatment option for second-line therapy of advanced GC. Clinical research data on novel targeted drugs hold promise for further improvement in GC patients’ outcomes. Currently the most studied targets in GC are HER family receptors, vascular endothelial growth factor proangiogenic pathway, and PI3K/Akt/mTOR axis. Also hepatocyte growth factor/mesenchymal epithelial transition factor, fibroblast growth factor receptor (FGFR) pathways and some other promising targets have emerged recently. This review is focused at the current progress in clinical research of targeted drugs for GC with the accent on recent studies and future perspectives.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):359–86. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):359–86.
2.
Zurück zum Zitat Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi57–63. PubMed Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi57–63. PubMed
3.
Zurück zum Zitat Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. PubMedCrossRef Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. PubMedCrossRef
4.
Zurück zum Zitat Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9. PubMedCrossRef Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9. PubMedCrossRef
5.
Zurück zum Zitat Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. PubMedCrossRef Bang YJ, Van CE, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. PubMedCrossRef
6.
Zurück zum Zitat Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol. 2013;31 (suppl; abstr LBA4001). Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol. 2013;31 (suppl; abstr LBA4001).
7.
Zurück zum Zitat Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–49. PubMedCrossRef Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–49. PubMedCrossRef
8.
Zurück zum Zitat Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–9. PubMedCentralPubMedCrossRef Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):481–9. PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9. PubMedCrossRef Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9. PubMedCrossRef
10.
Zurück zum Zitat Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 2014. [Epub ahead of print]. Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 2014. [Epub ahead of print].
11.
Zurück zum Zitat Wang L, Yuan H, Li Y, Han Y. The role of HER3 in gastric cancer. Biomed Pharmacother. 2014;68(6):809–12. PubMedCrossRef Wang L, Yuan H, Li Y, Han Y. The role of HER3 in gastric cancer. Biomed Pharmacother. 2014;68(6):809–12. PubMedCrossRef
12.
Zurück zum Zitat Ohtsu A, Shah MA, Van CE, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76. PubMedCrossRef Ohtsu A, Shah MA, Van CE, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968–76. PubMedCrossRef
13.
Zurück zum Zitat Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming XJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012 ;30(17):2119–27. PubMedCrossRef Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming XJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012 ;30(17):2119–27. PubMedCrossRef
15.
Zurück zum Zitat Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumabmonotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. PubMedCrossRef Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumabmonotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. PubMedCrossRef
16.
Zurück zum Zitat Wilke H, Muro K, Van CE, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. PubMedCrossRef Wilke H, Muro K, Van CE, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. PubMedCrossRef
17.
Zurück zum Zitat Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2014;32:5s (suppl; abstr 4003). Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2014;32:5s (suppl; abstr 4003).
18.
Zurück zum Zitat Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32:5 s (suppl; abstr 4004). Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol. 2014;32:5 s (suppl; abstr 4004).
19.
Zurück zum Zitat Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28(11):1904–10. PubMedCrossRef Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28(11):1904–10. PubMedCrossRef
20.
Zurück zum Zitat Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935–43. PubMedCrossRef Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935–43. PubMedCrossRef
21.
Zurück zum Zitat Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, et al. A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group Trial (S1005). J Clin Oncol. 2014;32:5s (suppl; abstr 4041). CrossRef Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, et al. A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group Trial (S1005). J Clin Oncol. 2014;32:5s (suppl; abstr 4041). CrossRef
22.
Zurück zum Zitat Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One. 2014;9(1):e84502. PubMedCentralPubMedCrossRef Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, et al. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One. 2014;9(1):e84502. PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014;20(6):1666–75. PubMedCrossRef Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014;20(6):1666–75. PubMedCrossRef
24.
Zurück zum Zitat Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15(9):1007–18. PubMedCrossRef Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15(9):1007–18. PubMedCrossRef
25.
Zurück zum Zitat Hale MD, Oliner KS, Tang R, Vallone JG, Klement I, Webster S, et al. Evaluation of MET staining in gastric/gastroesophageal junction (G/GEJ) tumor samples as a biomarker for rilotumumab benefit. Ann Oncol. 2014;25(Suppl 4):iv58–84. doi:10.1093/annonc/mdu326. Hale MD, Oliner KS, Tang R, Vallone JG, Klement I, Webster S, et al. Evaluation of MET staining in gastric/gastroesophageal junction (G/GEJ) tumor samples as a biomarker for rilotumumab benefit. Ann Oncol. 2014;25(Suppl 4):iv58–84. doi:10.1093/annonc/mdu326.
26.
Zurück zum Zitat Hong DS, LoRusso P, Hamid O, Beaupre D, Janku F, Khan R, et al. First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 2508). CrossRef Hong DS, LoRusso P, Hamid O, Beaupre D, Janku F, Khan R, et al. First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 2508). CrossRef
27.
Zurück zum Zitat Kilgour E, Su X, Zhan P, Gavine P, Morgan S, Womack C, et al. Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. J Clin Oncol. 2012;30 (suppl; abstr 4124). Kilgour E, Su X, Zhan P, Gavine P, Morgan S, Womack C, et al. Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts. J Clin Oncol. 2012;30 (suppl; abstr 4124).
28.
Zurück zum Zitat Arkenau HT, Saggese M, Hollebecque A, Mathewson A, Lemech CR, Landers D, et al. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 2620). CrossRef Arkenau HT, Saggese M, Hollebecque A, Mathewson A, Lemech CR, Landers D, et al. A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 2620). CrossRef
29.
Zurück zum Zitat Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(5):1662–72. PubMedCrossRef Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(5):1662–72. PubMedCrossRef
30.
Zurück zum Zitat Muro K, Bang Y, Shankaran V, Geva R, Catenacci DV, Gupta S, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced gastric cancer. Ann Oncol. 2014;25(5):1–41. doi:10.1093/annonc/mdu438. Muro K, Bang Y, Shankaran V, Geva R, Catenacci DV, Gupta S, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced gastric cancer. Ann Oncol. 2014;25(5):1–41. doi:10.1093/annonc/mdu438.
31.
Zurück zum Zitat Schuler MH, Zvirbule Z, Lordick F, Krilova A, Helbig U, Schulze-Bergkamen U, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. J Clin Oncol. 2013;31 (suppl; abstr 4080). Schuler MH, Zvirbule Z, Lordick F, Krilova A, Helbig U, Schulze-Bergkamen U, et al. Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. J Clin Oncol. 2013;31 (suppl; abstr 4080).
32.
Zurück zum Zitat Zambrano CC, Almhanna K, Messersmith WA, Ahnert JR, Ryan DP, Faris JE, et al. MLN0264, an investigational antiguanylylcyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: phase I study. J Clin Oncol. 2014;32:5s (suppl; abstr 3546). CrossRef Zambrano CC, Almhanna K, Messersmith WA, Ahnert JR, Ryan DP, Faris JE, et al. MLN0264, an investigational antiguanylylcyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: phase I study. J Clin Oncol. 2014;32:5s (suppl; abstr 3546). CrossRef
33.
Zurück zum Zitat Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study. J Clin Oncol. 2013;31 (suppl; abstr 4013). Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study. J Clin Oncol. 2013;31 (suppl; abstr 4013).
34.
Zurück zum Zitat Hitron M, Stephenson J, Chi KN, Edenfield WJ, Leggett D, Li Y, et al. A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. J Clin Oncol. 2014;32:5s (suppl; abstr 2530). CrossRef Hitron M, Stephenson J, Chi KN, Edenfield WJ, Leggett D, Li Y, et al. A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. J Clin Oncol. 2014;32:5s (suppl; abstr 2530). CrossRef
Metadaten
Titel
New targets in gastric cancer
verfasst von
MD, PhD Nikita M. Volkov
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0205-9